Who are Zavesca's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Glyset, Glustat, Cerdelga, Miglustat (Zavesca), Eliglustat GZ385660.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/miglustat.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Zavesca — Competitive Intelligence Brief

Zavesca (MIGLUSTAT) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glucosylceramide Synthase Inhibitor [EPC]. Area: Metabolic.

marketed Glucosylceramide Synthase Inhibitor [EPC] Lysosomal alpha-glucosidase Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Zavesca (MIGLUSTAT) — AstraZeneca. Zavesca works by inhibiting the enzyme glucosylceramide synthase, which is involved in the production of a toxic lipid that accumulates in cells of patients with certain lysosomal storage disorders.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zavesca TARGET	MIGLUSTAT	AstraZeneca	marketed	Glucosylceramide Synthase Inhibitor [EPC]	Lysosomal alpha-glucosidase	2003-01-01
Glyset	MIGLITOL	Pfizer	marketed	alpha-Glucosidase Inhibitor	Lysosomal alpha-glucosidase	1996-01-01
Glustat	VOGLIBOSE		marketed	voglibose	Lysosomal alpha-glucosidase	1994-01-01
Cerdelga	ELIGLUSTAT	Sanofi	marketed	Glucosylceramide Synthase Inhibitor [EPC]	Ceramide glucosyltransferase	2014-01-01
Miglustat (Zavesca)	Miglustat (Zavesca)	University of Washington	marketed	Glucosylceramide synthase inhibitor	Glucosylceramide synthase
Eliglustat GZ385660	Eliglustat GZ385660	Sanofi	phase 3	Glucosylceramide synthase inhibitor	Glucosylceramide synthase (GCS)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-03-07 — Zavesca · 12419937 · Method of Use · US
2033-03-07 — Zavesca · 11278599 · Method of Use · US
2033-03-07 — Zavesca · 10512677 · Method of Use · US
2035-09-30 — Zavesca · 10961522 · Method of Use · US
2035-09-30 — Zavesca · 10208299 · Compound · US
2035-09-30 — Zavesca · 11753632 · Method of Use · US
2036-12-29 — Zavesca · 11278601 · Formulation · US
2036-12-29 — Zavesca · 12414985 · Method of Use · US
2037-08-12 — Zavesca · 10857212 · Method of Use · US
2038-09-16 — Zavesca · 12246062 · Method of Use · US

Sponsor landscape (Glucosylceramide Synthase Inhibitor [EPC] class)

AstraZeneca · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zavesca — Competitive Intelligence Brief. https://druglandscape.com/ci/miglustat. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab